[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-001", "question": "A 16-year-old male presents with recurrent stroke-like episodes, mitochondrial myopathy, and lactic acidosis. Muscle biopsy reveals 38% heteroplasmy for the m.3243A>G mutation. Based on current mitochondrial disease criteria, what is the significance of this heteroplasmy level?", "options": ["Insufficient for MELAS diagnosis; >60% required in muscle", "Diagnostic of MELAS; clinical correlation unnecessary", "Above the threshold for clinical expression; supports diagnosis with compatible phenotype", "Only significant if confirmed in blood at >20%", "Requires repeat biopsy; sampling error likely"], "answer": "C", "answer_index": 2, "explanation": "In MELAS, >40% heteroplasmy in muscle correlates with clinical manifestation, but levels of 30-40% with typical phenotype are considered diagnostic. Blood heteroplasmy is less sensitive and declines with age. The threshold concept is critical for interpreting borderline results.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues include 16-year-old male with recurrent stroke-like episodes, mitochondrial myopathy, lactic acidosis, and 38% heteroplasmy for m.3243A>G in muscle, pointing to MELAS syndrome where heteroplasmy levels around 30-40% in muscle support diagnosis when phenotype matches. These findings uniquely favor option C, as it recognizes 38% as above typical thresholds for expression while requiring clinical correlation. Alternatives are inferior: A incorrectly demands >60% in muscle; B dismisses need for phenotype; D wrongly prioritizes blood levels (>20%), which are less reliable and age-dependent; E assumes sampling error without basis. No main logical issues; stem is consistent, allows discrimination, and supports unique best (C) matching key. Main medical accuracy issues: minor nuance in heteroplasmy thresholds—while >40% often correlates with symptoms per some sources, 30-40% levels are indeed diagnostic with compatible features per mitochondrial criteria (e.g., revised Bernier), but absolute thresholds vary by tissue and aren't strictly defined, potentially oversimplifying; overall aligns with USMLE-level knowledge on MELAS (m.3243A>G association, muscle biopsy utility). Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues include 16-year-old male with recurrent stroke-like episodes, mitochondrial myopathy, lactic acidosis, and 38% heteroplasmy for m.3243A>G in muscle, pointing to MELAS syndrome where heteroplasmy levels around 30-40% in muscle support diagnosis when phenotype matches. These findings uniquely favor option C, as it recognizes 38% as above typical thresholds for expression while requiring clinical correlation. Alternatives are inferior: A incorrectly demands >60% in muscle; B dismisses need for phenotype; D wrongly prioritizes blood levels (>20%), which are less reliable and age-dependent; E assumes sampling error without basis. No main logical issues; stem is consistent, allows discrimination, and supports unique best (C) matching key. Main medical accuracy issues: minor nuance in heteroplasmy thresholds—while >40% often correlates with symptoms per some sources, 30-40% levels are indeed diagnostic with compatible features per mitochondrial criteria (e.g., revised Bernier), but absolute thresholds vary by tissue and aren't strictly defined, potentially oversimplifying; overall aligns with USMLE-level knowledge on MELAS (m.3243A>G association, muscle biopsy utility). Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-002", "question": "A 19-year-old asymptomatic athlete has a QTc of 315ms on pre-participation screening. Family history reveals sudden cardiac death in a paternal uncle. Genetic testing identifies a gain-of-function KCNH2 mutation (c.1764G>C). According to 2022 ESC guidelines for SQTS, what is the recommended management?", "options": ["No therapy; restriction from competitive sports", "Implantable cardioverter-defibrillator regardless of symptoms", "Quinidine 600mg daily to maintain QTc >360ms", "Flecainide 100mg twice daily for rhythm stabilization", "Annual Holter monitoring without pharmacotherapy"], "answer": "C", "answer_index": 2, "explanation": "For asymptomatic SQTS patients with pathogenic KCNH2 mutations, quinidine is recommended to prolong QT interval and reduce arrhythmia risk. ICD is reserved for symptomatic patients or those with aborted SCD. Flecainide is contraindicated in SQTS.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include asymptomatic 19-year-old athlete with QTc 315ms, family history of sudden cardiac death in paternal uncle, and confirmed gain-of-function KCNH2 mutation, aligning with Short QT Syndrome (SQTS) diagnosis per 2022 ESC guidelines. These findings support quinidine as first-line therapy to prolong QTc >360ms and mitigate arrhythmia risk in asymptomatic patients with pathogenic KCNH2 variants. Main logical issue(s): None; the vignette provides sufficient details (age, symptoms, ECG, family history, genetics) to discriminate options without contradictions or underspecification, allowing unique selection of C as best. Option A (no therapy, restrict sports) is inferior as guidelines recommend pharmacotherapy; B (ICD regardless) is reserved for symptomatic or SCD survivors; D (flecainide) is contraindicated in SQTS; E (monitoring only) lacks risk reduction. Main medical accuracy issue(s): None; keyed answer aligns with 2022 ESC SQTS guidelines recommending quinidine for QT prolongation in asymptomatic KCNH2 mutation carriers, with ICD for higher-risk cases and flecainide avoidance. Item reflects current standards without inaccuracies or outdated elements. Minimal fix: None required; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include asymptomatic 19-year-old athlete with QTc 315ms, family history of sudden cardiac death in paternal uncle, and confirmed gain-of-function KCNH2 mutation, aligning with Short QT Syndrome (SQTS) diagnosis per 2022 ESC guidelines. These findings support quinidine as first-line therapy to prolong QTc >360ms and mitigate arrhythmia risk in asymptomatic patients with pathogenic KCNH2 variants. Main logical issue(s): None; the vignette provides sufficient details (age, symptoms, ECG, family history, genetics) to discriminate options without contradictions or underspecification, allowing unique selection of C as best. Option A (no therapy, restrict sports) is inferior as guidelines recommend pharmacotherapy; B (ICD regardless) is reserved for symptomatic or SCD survivors; D (flecainide) is contraindicated in SQTS; E (monitoring only) lacks risk reduction. Main medical accuracy issue(s): None; keyed answer aligns with 2022 ESC SQTS guidelines recommending quinidine for QT prolongation in asymptomatic KCNH2 mutation carriers, with ICD for higher-risk cases and flecainide avoidance. Item reflects current standards without inaccuracies or outdated elements. Minimal fix: None required; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-003", "question": "A 62-year-old woman with Graves disease presents in thyroid storm (Burch-Wartofsky score 65) with pulmonary edema and cardiogenic shock (LVEF 15%, CI 1.8 L/min/m²). She cannot tolerate beta-blockers due to severe decompensation. Which vasoactive agent is most appropriate initial therapy?", "options": ["Norepinephrine for vasopressor support", "Dobutamine for inotropic effect", "Milrinone 0.5 mcg/kg/min for inodilation", "Levosimendan 0.1 mcg/kg/min calcium sensitizer", "Dopamine 10 mcg/kg/min for combined effect"], "answer": "C", "answer_index": 2, "explanation": "In thyroid storm with cardiogenic shock, beta-blockers are contraindicated. Milrinone provides inotropy via phosphodiesterase inhibition independent of beta-adrenergic receptors and offers vasodilation to reduce afterload. Levosimendan is less preferred due to limited data and potential arrhythmogenicity.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues that drive (or fail to drive) a unique best answer: The vignette describes a 62-year-old woman with Graves disease in thyroid storm (Burch-Wartofsky score 65), presenting with pulmonary edema and cardiogenic shock (LVEF 15%, CI 1.8 L/min/m²), unable to tolerate beta-blockers due to severe decompensation. These point to a need for initial vasoactive therapy providing inotropic support and vasodilation without beta-adrenergic stimulation, given the hyperadrenergic state and shock. Positive clues: high storm severity, low cardiac output; negative: beta-blocker intolerance.\\nMain logical issue(s): Multiple answers defensible (M) as both C (milrinone) and D (levosimendan) are beta-independent inodilators suitable for cardiogenic shock; no stem details differentiate them (e.g., by evidence, availability, or risks). This stems from underspecification (U), requiring unstated assumptions about regional guidelines or drug profiles to select a unique best.\\nMain medical accuracy issue(s): Keyed answer C is consistent with mainstream US standards (e.g., ACC/AHA guidelines for heart failure), where milrinone is established for inodilation in shock; levosimendan has limited US data and no FDA approval but is used elsewhere. No major inaccuracies, though best answer depends on regional variation without harm risk.\\nMinimal fix: Add 'in the United States' to the stem to specify context favoring milrinone over levosimendan.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues that drive (or fail to drive) a unique best answer: The vignette describes a 62-year-old woman with Graves disease in thyroid storm (Burch-Wartofsky score 65), presenting with pulmonary edema and cardiogenic shock (LVEF 15%, CI 1.8 L/min/m²), unable to tolerate beta-blockers due to severe decompensation. These point to a need for initial vasoactive therapy providing inotropic support and vasodilation without beta-adrenergic stimulation, given the hyperadrenergic state and shock. Positive clues: high storm severity, low cardiac output; negative: beta-blocker intolerance.\nMain logical issue(s): Multiple answers defensible (M) as both C (milrinone) and D (levosimendan) are beta-independent inodilators suitable for cardiogenic shock; no stem details differentiate them (e.g., by evidence, availability, or risks). This stems from underspecification (U), requiring unstated assumptions about regional guidelines or drug profiles to select a unique best.\nMain medical accuracy issue(s): Keyed answer C is consistent with mainstream US standards (e.g., ACC/AHA guidelines for heart failure), where milrinone is established for inodilation in shock; levosimendan has limited US data and no FDA approval but is used elsewhere. No major inaccuracies, though best answer depends on regional variation without harm risk.\nMinimal fix: Add 'in the United States' to the stem to specify context favoring milrinone over levosimendan.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-004", "question": "A 6-year-old boy presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis. ADA2 enzyme activity is <5% of normal. Genetic testing confirms biallelic loss-of-function ADA2 mutations. What is the first-line therapy for preventing further cerebrovascular events?", "options": ["High-dose prednisone with cyclophosphamide induction", "Rituximab 750mg/m² every 4 weeks", "Etanercept 0.8mg/kg weekly subcutaneously", "Anakinra 2mg/kg daily subcutaneously", "Aspirin 5mg/kg daily antiplatelet therapy"], "answer": "C", "answer_index": 2, "explanation": "DADA2 is a monogenic interferonopathy where TNF-α drives vasculitic manifestations. TNF inhibition with etanercept prevents stroke recurrence and treats systemic vasculitis, while traditional immunosuppressants are ineffective. IL-1 blockade is second-line.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 6-year-old boy with recurrent lacunar strokes, livedo racemosa, systemic vasculitis, ADA2 activity <5% normal, and confirmed biallelic loss-of-function ADA2 mutations, pointing to deficiency of adenosine deaminase 2 (DADA2), a monogenic autoinflammatory vasculitis. These findings imply the need for targeted therapy to prevent cerebrovascular events, with TNF-α inhibition as first-line based on pathophysiology. Main logical issue(s): None; the vignette provides sufficient discriminating details (genetic confirmation, low enzyme activity, specific manifestations) to identify etanercept as the unique best option without contradictions or underspecification. Alternatives are clearly inferior: A (traditional immunosuppressants) ineffective in DADA2; B (rituximab) not targeted; D (anakinra) second-line IL-1 blockade; E (aspirin) addresses only thrombosis, not underlying inflammation. Main medical accuracy issue(s): None; aligns with current standards where TNF inhibitors like etanercept prevent stroke recurrence in DADA2, per guidelines and literature (e.g., NIH studies); rationale correctly notes TNF-driven pathology and inefficacy of traditional agents. Minimal fix: None needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 6-year-old boy with recurrent lacunar strokes, livedo racemosa, systemic vasculitis, ADA2 activity <5% normal, and confirmed biallelic loss-of-function ADA2 mutations, pointing to deficiency of adenosine deaminase 2 (DADA2), a monogenic autoinflammatory vasculitis. These findings imply the need for targeted therapy to prevent cerebrovascular events, with TNF-α inhibition as first-line based on pathophysiology. Main logical issue(s): None; the vignette provides sufficient discriminating details (genetic confirmation, low enzyme activity, specific manifestations) to identify etanercept as the unique best option without contradictions or underspecification. Alternatives are clearly inferior: A (traditional immunosuppressants) ineffective in DADA2; B (rituximab) not targeted; D (anakinra) second-line IL-1 blockade; E (aspirin) addresses only thrombosis, not underlying inflammation. Main medical accuracy issue(s): None; aligns with current standards where TNF inhibitors like etanercept prevent stroke recurrence in DADA2, per guidelines and literature (e.g., NIH studies); rationale correctly notes TNF-driven pathology and inefficacy of traditional agents. Minimal fix: None needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-005", "question": "A 30-year-old G2P1 at 32 weeks gestation presents with fetal hydrops and mirror syndrome. Which pathophysiologic mechanism best explains her severe preeclampsia-like features?", "options": ["Massive fetomaternal hemorrhage causing maternal anemia", "Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1)", "Maternal antibody production against fetal Rh antigens", "Amniotic fluid embolism triggering systemic inflammation", "Mirror syndrome is a misdiagnosis; this is atypical HELLP"], "answer": "B", "answer_index": 1, "explanation": "Mirror syndrome involves placental edema that mechanically compromises uteroplacental perfusion and releases anti-angiogenic factors like sFlt-1, creating a preeclampsia phenotype. Resolution occurs within 48 hours of delivery or fetal therapy that reduces hydrops.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 30-year-old G2P1 at 32 weeks with fetal hydrops and mirror syndrome presenting severe preeclampsia-like features; question asks for pathophysiologic mechanism. Clues imply maternal edema and hypertension mirroring fetal hydrops, driven by placental factors. B fits via placental edema releasing sFlt-1, an anti-angiogenic factor causing preeclampsia phenotype. Alternatives: A involves hemorrhage/anemia, not preeclampsia; C is alloimmunization causing hydrops but not maternal syndrome; D is acute embolism, mismatched; E denies diagnosis despite stem confirmation.\\nMain logical issue(s), if any: None; stem supports unique best answer without contradictions or underspecification.\\nMain medical accuracy issue(s), if any: None; aligns with current understanding of mirror syndrome pathophysiology involving sFlt-1 release from edematous placenta, per major obstetric guidelines (e.g., ACOG-level knowledge). Resolution post-delivery/fetal therapy is accurate.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 30-year-old G2P1 at 32 weeks with fetal hydrops and mirror syndrome presenting severe preeclampsia-like features; question asks for pathophysiologic mechanism. Clues imply maternal edema and hypertension mirroring fetal hydrops, driven by placental factors. B fits via placental edema releasing sFlt-1, an anti-angiogenic factor causing preeclampsia phenotype. Alternatives: A involves hemorrhage/anemia, not preeclampsia; C is alloimmunization causing hydrops but not maternal syndrome; D is acute embolism, mismatched; E denies diagnosis despite stem confirmation.\nMain logical issue(s), if any: None; stem supports unique best answer without contradictions or underspecification.\nMain medical accuracy issue(s), if any: None; aligns with current understanding of mirror syndrome pathophysiology involving sFlt-1 release from edematous placenta, per major obstetric guidelines (e.g., ACOG-level knowledge). Resolution post-delivery/fetal therapy is accurate.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-006", "question": "A 50-year-old with eosinophilic granulomatosis with polyangiitis undergoes cardiac MRI for suspected myocarditis. Late gadolinium enhancement shows predominant subendocardial involvement with sparing of the epicardium. What is the prognostic implication?", "options": ["Indicates active eosinophilic myocarditis responsive to steroids", "Suggests concomitant coronary artery disease requiring angiography", "Represents fibrotic replacement predicting poor response to immunosuppression", "Typical pattern with no impact on treatment decisions", "Requires endomyocardial biopsy for definitive diagnosis"], "answer": "C", "answer_index": 2, "explanation": "In EGPA, subendocardial LGE pattern indicates chronic fibrotic replacement rather than active inflammation, predicting poor response to immunosuppressive therapy and worse cardiac outcomes. Epicardial LGE correlates with active myocarditis and treatment responsiveness.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The clinical problem asks for the prognostic implication of subendocardial late gadolinium enhancement (LGE) with epicardial sparing on cardiac MRI in a 50-year-old with eosinophilic granulomatosis with polyangiitis (EGPA) and suspected myocarditis. Key stem clues: EGPA history, suspected myocarditis, predominant subendocardial LGE, epicardial sparing—these drive toward chronic fibrosis rather than active inflammation, implying poor response to immunosuppression and worse outcomes. The most likely implication is fibrotic replacement, making C the unique best answer as it directly addresses prognostic poor response. Keyed answer C fits: subendocardial pattern in EGPA indicates chronic fibrotic changes, not active myocarditis (which shows epicardial involvement), per standard cardiac MRI interpretations. Alternatives: A incorrect as subendocardial suggests chronic, not active/responsive; B assumes CAD but stem lacks ischemic clues; D wrong as pattern impacts prognosis/treatment; E unnecessary as MRI provides prognostic insight without biopsy. No main logical issues; stem allows unique discrimination without contradictions or underspecification. No medical accuracy issues; aligns with current guidelines on EGPA cardiac involvement, where subendocardial LGE predicts fibrosis and poor immunosuppression response, while epicardial indicates activity. Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The clinical problem asks for the prognostic implication of subendocardial late gadolinium enhancement (LGE) with epicardial sparing on cardiac MRI in a 50-year-old with eosinophilic granulomatosis with polyangiitis (EGPA) and suspected myocarditis. Key stem clues: EGPA history, suspected myocarditis, predominant subendocardial LGE, epicardial sparing—these drive toward chronic fibrosis rather than active inflammation, implying poor response to immunosuppression and worse outcomes. The most likely implication is fibrotic replacement, making C the unique best answer as it directly addresses prognostic poor response. Keyed answer C fits: subendocardial pattern in EGPA indicates chronic fibrotic changes, not active myocarditis (which shows epicardial involvement), per standard cardiac MRI interpretations. Alternatives: A incorrect as subendocardial suggests chronic, not active/responsive; B assumes CAD but stem lacks ischemic clues; D wrong as pattern impacts prognosis/treatment; E unnecessary as MRI provides prognostic insight without biopsy. No main logical issues; stem allows unique discrimination without contradictions or underspecification. No medical accuracy issues; aligns with current guidelines on EGPA cardiac involvement, where subendocardial LGE predicts fibrosis and poor immunosuppression response, while epicardial indicates activity. Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-007", "question": "An 11-month-old infant presents with a large CNS tumor. Histopathology shows rhabdoid cells with loss of SMARCB1 immunostaining. Molecular profiling reveals a TYR-methylation class. What is the most critical prognostic factor in this subtype?", "options": ["Presence of SMARCB1 deletion alone", "Age <3 years at diagnosis", "MYC oncogene amplification status", "DNA methylation subclassification", "Extent of surgical resection"], "answer": "D", "answer_index": 3, "explanation": "In ATRT, the methylation class (TYR, SHH, MYC) is the dominant prognostic factor, with TYR class having 90% 5-year survival compared to <30% for MYC. SMARCB1 loss is universal, and age is secondary to molecular subclassification in risk stratification.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C. Verdict on keyed answer: Not uniquely determinable. Key stem clues: 11-month-old infant with large CNS tumor, rhabdoid cells, loss of SMARCB1 immunostaining, TYR-methylation class; question asks for most critical prognostic factor in this subtype (TYR class of ATRT). These drive toward recognizing ATRT-TYR, which has favorable prognosis, but fail to support a unique best answer due to phrasing. Main logical issue(s): Internal contradiction—the stem specifies TYR-methylation class as the subtype, rendering D (DNA methylation subclassification) circular and incoherent as a variable prognostic factor within it, making the item unsolvable. No other option clearly emerges as uniquely best without assumptions. Main medical accuracy issue(s): None; vignette accurately describes ATRT features (rhabdoid histology, SMARCB1 loss), and rationale correctly notes methylation classes (TYR better than MYC) as key prognosticators per current guidelines (e.g., WHO CNS tumors). Minimal fix: Revise question stem to 'What is the most critical prognostic factor for atypical teratoid rhabdoid tumors?' to eliminate circular reference to 'this subtype.' Best-answer defensibility: a) Question asks most critical prognostic factor in ATRT-TYR. b) Discriminating findings: young age, CNS location, rhabdoid/SMARCB1 loss, TYR class. c) Implied diagnosis: ATRT-TYR with good prognosis. d) Keyed D fits overall ATRT but assumes subclass varies within subtype, requiring illogical assumption. e) A worse: universal in ATRT, not prognostic; B possible but secondary; C irrelevant for TYR; E defensible (resection impacts survival) but not uniquely.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C. Verdict on keyed answer: Not uniquely determinable. Key stem clues: 11-month-old infant with large CNS tumor, rhabdoid cells, loss of SMARCB1 immunostaining, TYR-methylation class; question asks for most critical prognostic factor in this subtype (TYR class of ATRT). These drive toward recognizing ATRT-TYR, which has favorable prognosis, but fail to support a unique best answer due to phrasing. Main logical issue(s): Internal contradiction—the stem specifies TYR-methylation class as the subtype, rendering D (DNA methylation subclassification) circular and incoherent as a variable prognostic factor within it, making the item unsolvable. No other option clearly emerges as uniquely best without assumptions. Main medical accuracy issue(s): None; vignette accurately describes ATRT features (rhabdoid histology, SMARCB1 loss), and rationale correctly notes methylation classes (TYR better than MYC) as key prognosticators per current guidelines (e.g., WHO CNS tumors). Minimal fix: Revise question stem to 'What is the most critical prognostic factor for atypical teratoid rhabdoid tumors?' to eliminate circular reference to 'this subtype.' Best-answer defensibility: a) Question asks most critical prognostic factor in ATRT-TYR. b) Discriminating findings: young age, CNS location, rhabdoid/SMARCB1 loss, TYR class. c) Implied diagnosis: ATRT-TYR with good prognosis. d) Keyed D fits overall ATRT but assumes subclass varies within subtype, requiring illogical assumption. e) A worse: universal in ATRT, not prognostic; B possible but secondary; C irrelevant for TYR; E defensible (resection impacts survival) but not uniquely.", "medical_accuracy_score": 5, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-008", "question": "A 76-year-old man with wild-type transthyretin amyloidosis (ATTRwt) has LV wall thickness 16mm and LVEF 45%. Which speckle-tracking echocardiographic finding best distinguishes this from hypertensive heart disease?", "options": ["Global longitudinal strain -8%", "Relative apical sparing ratio >1.5", "Basal sparing pattern", "Circumferential strain >-15%", "Longitudinal strain <10% with basal predominance"], "answer": "B", "answer_index": 1, "explanation": "Relative apical sparing ratio (average apical strain / average basal strain) >1.5 is 93% specific for cardiac amyloidosis, reflecting base-to-apex gradient of amyloid deposition. This pattern is not seen in hypertensive heart disease where strain reduction is homogeneous.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 76-year-old man with ATTRwt amyloidosis, LV wall thickness 16mm, LVEF 45%; question seeks speckle-tracking echo finding distinguishing from hypertensive heart disease. The vignette implies a hypertrophic phenotype, and the keyed answer B (relative apical sparing ratio >1.5) aligns with the characteristic base-to-apex strain gradient in amyloidosis, where apical strain is relatively preserved compared to basal, unlike homogeneous strain reduction in hypertension. Main logical issue(s): None; stem provides sufficient details for discrimination without contradictions or underspecification, allowing unique best answer. Alternatives are inferior: A (global LS -8%) indicates nonspecific impairment; C (basal sparing) reverses the typical pattern; D (circumferential strain >-15%) reflects general dysfunction, not distinguishing; E (LS <10% with basal predominance) vaguely describes basal impairment but lacks the specific ratio's quantitation and validated specificity. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., ESC, AHA) on strain imaging in amyloidosis, where apical sparing ratio >1 is highly specific (>90%) vs. hypertension. Minimal fix: Not needed, as item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 76-year-old man with ATTRwt amyloidosis, LV wall thickness 16mm, LVEF 45%; question seeks speckle-tracking echo finding distinguishing from hypertensive heart disease. The vignette implies a hypertrophic phenotype, and the keyed answer B (relative apical sparing ratio >1.5) aligns with the characteristic base-to-apex strain gradient in amyloidosis, where apical strain is relatively preserved compared to basal, unlike homogeneous strain reduction in hypertension. Main logical issue(s): None; stem provides sufficient details for discrimination without contradictions or underspecification, allowing unique best answer. Alternatives are inferior: A (global LS -8%) indicates nonspecific impairment; C (basal sparing) reverses the typical pattern; D (circumferential strain >-15%) reflects general dysfunction, not distinguishing; E (LS <10% with basal predominance) vaguely describes basal impairment but lacks the specific ratio's quantitation and validated specificity. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., ESC, AHA) on strain imaging in amyloidosis, where apical sparing ratio >1 is highly specific (>90%) vs. hypertension. Minimal fix: Not needed, as item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-009", "question": "A 45-year-old woman with severe verapamil overdose (ingestion 4 hours ago) presents with hypotension (SBP 70mmHg) and hyperglycemia (420mg/dL). You initiate high-dose insulin euglycemia therapy (HIET). What is the target serum glucose range during the first 24 hours?", "options": ["80-110 mg/dL (tight glycemic control)", "110-180 mg/dL (moderate control)", "180-250 mg/dL (permissive hyperglycemia)", "250-350 mg/dL (severe hyperglycemia acceptable)", "No specific target; follow institutional protocol"], "answer": "B", "answer_index": 1, "explanation": "HIET requires maintaining glucose 110-180 mg/dL to prevent hypoglycemia during high-dose insulin infusion (0.5-1 unit/kg/hr) while allowing insulin's inotropic effects. Tighter targets risk hypoglycemia; higher targets may impair insulin's metabolic benefits.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Severe verapamil overdose with hypotension (SBP 70 mmHg) and hyperglycemia (420 mg/dL), initiation of HIET 4 hours post-ingestion; question asks for target serum glucose range in first 24 hours. These drive a unique best answer by implying need for euglycemic control during high-dose insulin to counter CCB toxicity's cardiogenic shock and hyperglycemia, without risking hypoglycemia. Main logical issue(s): None; stem provides sufficient details for discrimination—options vary by glycemic stringency, allowing B as clearly superior based on preventing hypoglycemia while supporting insulin's inotropic effects. Main medical accuracy issue(s): None; aligns with mainstream guidelines (e.g., Tox guidelines, ASHP) for HIET in CCB overdose, targeting euglycemia ~110-180 mg/dL to balance insulin benefits and avoid hypoglycemic complications; rationale correctly notes risks of tighter or looser control. Minimal fix: Not needed, as item is unambiguous and accurate. The clinical problem restated: Optimal glucose target for HIET in verapamil toxicity. Discriminating findings: Hypotension, hyperglycemia, recent ingestion. Implied management: Maintain moderate euglycemia. Keyed B fits: Prevents hypoglycemia, optimizes insulin. Alternatives: A too tight (hypoglycemia risk); C permissive (may reduce efficacy); D excessive (unnecessary); E incorrect (guidelines specify targets).\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Severe verapamil overdose with hypotension (SBP 70 mmHg) and hyperglycemia (420 mg/dL), initiation of HIET 4 hours post-ingestion; question asks for target serum glucose range in first 24 hours. These drive a unique best answer by implying need for euglycemic control during high-dose insulin to counter CCB toxicity's cardiogenic shock and hyperglycemia, without risking hypoglycemia. Main logical issue(s): None; stem provides sufficient details for discrimination—options vary by glycemic stringency, allowing B as clearly superior based on preventing hypoglycemia while supporting insulin's inotropic effects. Main medical accuracy issue(s): None; aligns with mainstream guidelines (e.g., Tox guidelines, ASHP) for HIET in CCB overdose, targeting euglycemia ~110-180 mg/dL to balance insulin benefits and avoid hypoglycemic complications; rationale correctly notes risks of tighter or looser control. Minimal fix: Not needed, as item is unambiguous and accurate. The clinical problem restated: Optimal glucose target for HIET in verapamil toxicity. Discriminating findings: Hypotension, hyperglycemia, recent ingestion. Implied management: Maintain moderate euglycemia. Keyed B fits: Prevents hypoglycemia, optimizes insulin. Alternatives: A too tight (hypoglycemia risk); C permissive (may reduce efficacy); D excessive (unnecessary); E incorrect (guidelines specify targets).", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-010", "question": "A 35-year-old man develops DRESS syndrome 3 weeks after starting phenytoin. He has fever, eosinophilia, atypical lymphocytosis, and transaminitis (AST 450 U/L). HHV-6 PCR becomes positive at day 16 of illness. What is the clinical significance of this virologic finding?", "options": ["Confirms phenytoin as the causative drug", "Indicates need for ganciclovir antiviral therapy", "Predicts higher risk of disease flare and organ damage", "Represents asymptomatic viral reactivation without prognostic value", "Suggests alternative diagnosis of acute HHV-6 infection"], "answer": "C", "answer_index": 2, "explanation": "HHV-6 reactivation at weeks 2-3 in DRESS is pathogenically linked to disease severity, predicting higher risk of relapse, end-organ damage, and prolonged course. It indicates need for more aggressive immunosuppression, not antiviral therapy, as the virus is a marker of immune dysregulation.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 35-year-old with DRESS syndrome 3 weeks post-phenytoin initiation, presenting with fever, eosinophilia, atypical lymphocytosis, transaminitis (AST 450 U/L), and HHV-6 PCR positivity at day 16 of illness. The question asks for the clinical significance of the HHV-6 finding in this established DRESS context.\\nMain logical issue(s), if any: None; the vignette provides sufficient details to discriminate options without contradictions or underspecification. HHV-6 reactivation in DRESS is a known marker of severity, uniquely supporting C as best while eliminating others (A doesn't confirm causality, B misdirects to antivirals not indicated, D understates prognostic value, E ignores DRESS context favoring reactivation over primary infection).\\nMain medical accuracy issue(s), if any: None; aligns with current understanding that HHV-6 reactivation in DRESS (typically weeks 2-3) correlates with increased risk of flares, organ damage, relapse, and prolonged course, warranting closer monitoring and potentially escalated immunosuppression, not antivirals. This reflects mainstream guidelines and literature (e.g., associations in severe drug hypersensitivity syndromes).\\nMinimal fix: No edit needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 35-year-old with DRESS syndrome 3 weeks post-phenytoin initiation, presenting with fever, eosinophilia, atypical lymphocytosis, transaminitis (AST 450 U/L), and HHV-6 PCR positivity at day 16 of illness. The question asks for the clinical significance of the HHV-6 finding in this established DRESS context.\nMain logical issue(s), if any: None; the vignette provides sufficient details to discriminate options without contradictions or underspecification. HHV-6 reactivation in DRESS is a known marker of severity, uniquely supporting C as best while eliminating others (A doesn't confirm causality, B misdirects to antivirals not indicated, D understates prognostic value, E ignores DRESS context favoring reactivation over primary infection).\nMain medical accuracy issue(s), if any: None; aligns with current understanding that HHV-6 reactivation in DRESS (typically weeks 2-3) correlates with increased risk of flares, organ damage, relapse, and prolonged course, warranting closer monitoring and potentially escalated immunosuppression, not antivirals. This reflects mainstream guidelines and literature (e.g., associations in severe drug hypersensitivity syndromes).\nMinimal fix: No edit needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]